News

New data was recently presented regarding Actelion Pharmaceuticals’ therapies and strategies to improve clinical outcomes in patients with pulmonary arterial hypertension (PAH). The data were presented at the Actelion Satellite Symposium, titled “Improving outcome in pulmonary arterial hypertension,” which was part of the 4th Systemic Sclerosis World Congress held in…

The AMBITION trial was truly a “landmark study,” Dr. Mihaela Ianosev said in an interview with Scleroderma News Today at the 4th Systemic Sclerosis World Congress, both for daring to take clinical failure — a physician’s emphasis — as its primary endpoint, and for marking “an evolution” in clinical…

At the 4th Systemic Sclerosis World Congress, recently held in Lisbon, Portugal, an international team of researchers led by Dr. Yannick Allanore from the Department of Rheumatology A, Paris Descartes University, in France, suggested a valuable predictor of mortality in patients with systemic sclerosis (SSc). The presentation was…

Digital ulcers have a significant clinical burden in patients with systemic sclerosis. In a study presented today, Feb. 19, at the 4th Systemic Sclerosis World Congress (Feb. 18-20) in Lisbon, Portugal, an international team of researchers revealed that a medical history of digital ulcers in the past 24 weeks should trigger…

A EUSTAR study on organ manifestations in the early course of systemic sclerosis (SSc) was presented today, Feb. 19, by Dr. V.K. Jaeger at the 4th Systemic Sclerosis World Congress, now underway in Lisbon, Portugal. The presentation was titled “Incidences and Predictors of Organ Manifestations in the Early…

https://sclerodermanews.com/wp-content/uploads/videos/Sequence%2001_1.mp4             Scleroderma News Today’s exclusive interview with Professor Christopher Denton, lead investigator of two Phase 3 clinical trials assessing Bayer’s class of sGC stimulators, Adempas, in PAH and PAH-CTD patients.   The 4th Systemic Sclerosis World Congress opened on Friday with a…

A team of researchers from University College London and Actelion Pharmaceuticals showed that macitentan (Opsumit) can prevent pulmonary arterial hypertension (PAH) in a mouse model of systemic sclerosis (SSc) by preventing heart tissue remodeling and functional changes. The results were presented this week by E. Derrett-Smith at the 4th…

Men with systemic sclerosis (SSc) who develop pulmonary arterial hypertension (PAH) tend to have poorer survival rates in  the first five years after diagnosis, a University of Toronto study reported. Men were also found to develop PAH at an earlier stage in comparison to women, and to suffer a more…

Cytori Therapeutics recently announced its participation in the 4th World Systemic Sclerosis World Congress taking place Feb. 18-20, 2016, in Lisbon, Portugal. In a presentation titled “Treating Scleroderma of the Face and Hands with Fat and Stromal Vascular Fraction,” Professor Guy Magalon from the Assistance Publique des Hôpitaux…

Patients with connective tissue disease or systemic sclerosis associated with pulmonary arterial hypertension (PAH) who are positive for anti-U1 RNP antibodies have more a favorable disease prognosis than patients without these antibodies, a study published in the journal Arthritis & Rheumatology showed. Anti-U1 RNP antibodies are autoantibodies directed at nuclear proteins. They are…